Rigel Pharmaceuticals (RIGL) Financials

$20.12 +0.42 (+2.13%)

Closing price 05/20/2025 04:00 PM Eastern

Extended Trading

$19.96 -0.16 (-0.77%)

As of 08:31 AM Eastern

Annual Income Statements for Rigel Pharmaceuticals

This table shows Rigel Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	17	-25	-59
Consolidated Net Income / (Loss)	17	-25	-59
Net Income / (Loss) Continuing Operations	17	-25	-59
Total Pre-Tax Income	18	-25	-59
Total Operating Income	24	-20	-56
Total Gross Profit	161	110	118
Total Revenue	179	117	120
Operating Revenue	179	117	120
Total Cost of Revenue	19	7.11	1.75
Operating Cost of Revenue	19	7.11	1.75
Total Operating Expenses	136	130	174
Selling, General & Admin Expense	113	106	112
Research & Development Expense	23	25	60
Restructuring Charge	0.00	0.00	1.32
Total Other Income / (Expense), net	-5.83	-4.60	-3.02
Interest Expense	7.92	6.87	3.71
Interest & Investment Income	2.09	2.27	0.68
Income Tax Expense	0.88	0.00	0.00
Basic Earnings per Share	$0.99	($1.44)	($3.44)
Weighted Average Basic Shares Outstanding	17.58M	17.40M	17.05M
Diluted Earnings per Share	$0.99	($1.44)	($3.44)
Weighted Average Diluted Shares Outstanding	17.69M	17.40M	17.05M
Weighted Average Basic & Diluted Shares Outstanding	17.86M	175.38M	173.65M

This table shows Rigel Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	14	12	-1.03	-8.25	0.74	-5.69	-6.60	-14	1.40	-19
Consolidated Net Income / (Loss)	14	12	-1.03	-8.25	0.74	-5.69	-6.60	-14	1.40	-19
Net Income / (Loss) Continuing Operations	14	12	-1.03	-8.25	0.74	-5.69	-6.60	-14	1.40	-19
Total Pre-Tax Income	15	12	-1.03	-8.25	0.74	-5.69	-6.60	-14	1.40	-19
Total Operating Income	17	14	0.45	-6.97	1.97	-4.47	-5.27	-13	2.08	-18
Total Gross Profit	52	47	34	28	32	27	26	25	51	22
Total Revenue	58	55	37	30	36	28	27	26	51	22
Operating Revenue	58	55	37	30	36	28	27	26	51	22
Total Cost of Revenue	5.79	8.03	2.81	2.03	3.79	1.27	1.08	0.98	0.34	0.25
Operating Cost of Revenue	5.79	8.03	2.81	2.03	3.79	1.27	1.08	0.98	0.34	0.25
Total Operating Expenses	35	33	34	34	30	31	31	38	49	41
Selling, General & Admin Expense	30	27	28	28	27	25	26	28	32	26
Research & Development Expense	5.63	6.18	5.54	6.03	3.19	6.48	4.77	10	15	15
Total Other Income / (Expense), net	-1.43	-1.64	-1.48	-1.28	-1.23	-1.23	-1.33	-0.81	-0.68	-0.63
Interest Expense	1.96	2.06	2.03	1.87	1.91	1.90	1.86	1.20	1.11	0.83
Interest & Investment Income	0.52	0.43	0.55	0.59	0.68	0.67	0.53	0.39	0.43	0.19
Basic Earnings per Share	$0.82	$0.71	($0.06)	($0.05)	$0.04	($0.33)	($0.38)	($0.08)	$0.08	($0.11)
Weighted Average Basic Shares Outstanding	17.58M	17.60M	17.55M	175.20M	17.40M	17.44M	17.36M	173.57M	17.05M	172.84M
Diluted Earnings per Share	$0.82	$0.70	($0.06)	($0.05)	$0.04	($0.33)	($0.38)	($0.08)	$0.08	($0.11)
Weighted Average Diluted Shares Outstanding	17.69M	17.65M	17.55M	175.20M	17.40M	17.44M	17.36M	173.57M	17.05M	172.84M
Basic & Diluted Earnings per Share	$0.82	-	-	-	$0.04	-	-	-	$0.08	-
Weighted Average Basic & Diluted Shares Outstanding	17.86M	17.62M	17.59M	175.41M	175.38M	174.37M	174.36M	173.67M	173.65M	172.84M

This table details how cash moves in and out of Rigel Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	24	8.33	5.57
Net Cash From Operating Activities	31	-5.74	-74
Net Cash From Continuing Operating Activities	31	-5.74	-74
Net Income / (Loss) Continuing Operations	17	-25	-59
Consolidated Net Income / (Loss)	17	-25	-59
Depreciation Expense	2.23	1.24	1.00
Amortization Expense	-0.71	-0.48	-0.06
Non-Cash Adjustments To Reconcile Net Income	12	9.07	13
Changes in Operating Assets and Liabilities, net	0.15	9.52	-29
Net Cash From Investing Activities	4.13	-4.30	73
Net Cash From Continuing Investing Activities	4.13	-4.30	73
Purchase of Property, Plant & Equipment	-0.04	0.00	-
Acquisitions	-0.36	-15	0.00
Purchase of Investments	-35	-31	-29
Sale of Property, Plant & Equipment	0.10	0.26	0.89
Sale and/or Maturity of Investments	40	42	101
Net Cash From Financing Activities	-12	18	6.55
Net Cash From Continuing Financing Activities	-12	18	6.55
Issuance of Debt	0.00	20	20
Issuance of Common Equity	1.96	1.05	2.12
Other Financing Activities, net	-14	-2.63	-15
Cash Interest Paid	7.04	5.85	2.50
Cash Income Taxes Paid	0.33	0.00	0.00

This table details how cash moves in and out of Rigel Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	5.05	16	10	-7.21	-13	-3.40	8.53	16	-5.41	2.67
Net Cash From Operating Activities	15	22	0.30	-5.01	-6.24	-1.36	5.93	-4.07	-22	-13
Net Cash From Continuing Operating Activities	15	22	0.30	-5.01	-6.24	-1.36	5.93	-4.07	-22	-13
Net Income / (Loss) Continuing Operations	14	12	-1.03	-8.25	0.74	-5.69	-6.60	-14	1.40	-19
Consolidated Net Income / (Loss)	14	12	-1.03	-8.25	0.74	-5.69	-6.60	-14	1.40	-19
Depreciation Expense	0.60	0.61	0.61	0.40	0.29	0.29	0.30	0.36	0.28	0.24
Amortization Expense	-0.28	-0.07	-0.16	-0.21	-0.26	-0.11	-0.05	-0.07	-0.18	0.01
Non-Cash Adjustments To Reconcile Net Income	2.03	2.62	2.53	5.13	1.82	1.92	2.22	3.11	4.41	2.50
Changes in Operating Assets and Liabilities, net	-2.20	6.10	-1.65	-2.10	-8.83	2.23	10	6.07	-28	2.99
Net Cash From Investing Activities	-11	3.80	11	0.31	-6.87	-1.17	2.97	0.78	19	10
Net Cash From Continuing Investing Activities	-11	3.80	11	0.31	-6.87	-1.17	2.97	0.78	19	10
Purchase of Property, Plant & Equipment	-0.03	-	-	-	-	-	-	-	-	-0.19
Purchase of Investments	-18	-2.21	-7.55	-7.80	-13	-9.44	-8.78	0.00	-2.85	-19
Sale of Property, Plant & Equipment	0.07	0.03	-	0.00	0.11	0.02	-	0.13	0.35	0.28
Sale and/or Maturity of Investments	6.75	6.00	19	8.25	6.00	8.25	12	16	21	29
Net Cash From Financing Activities	1.47	-9.84	-0.75	-2.51	0.49	-0.87	-0.37	19	-2.10	5.51
Net Cash From Continuing Financing Activities	1.47	-9.84	-0.75	-2.51	0.49	-0.87	-0.37	19	-2.10	5.51
Issuance of Common Equity	1.47	0.16	0.25	0.09	0.49	0.01	0.55	0.00	0.59	-
Cash Interest Paid	1.75	1.84	1.77	1.68	1.68	1.68	1.47	1.01	0.95	0.60

This table presents Rigel Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	164	117	134
Total Current Assets	135	99	116
Cash & Equivalents	57	33	24
Short-Term Investments	21	24	34
Accounts Receivable	42	31	40
Inventories, net	6.00	5.52	9.12
Prepaid Expenses	10	6.26	8.26
Plant, Property, & Equipment, net	0.09	0.17	0.86
Total Noncurrent Assets	29	18	18
Goodwill	27	14	15
Other Noncurrent Operating Assets	1.68	3.92	2.57
Total Liabilities & Shareholders' Equity	164	117	134
Total Liabilities	161	146	148
Total Current Liabilities	63	53	65
Short-Term Debt	7.27	7.23	0.00
Accounts Payable	3.34	7.14	23
Accrued Expenses	14	8.85	14
Current Deferred Revenue	1.36	1.36	1.37
Current Employee Benefit Liabilities	10	8.68	8.87
Other Current Liabilities	27	20	18
Total Noncurrent Liabilities	97	93	83
Long-Term Debt	52	52	39
Capital Lease Obligations	0.00	0.29	0.97
Other Noncurrent Operating Liabilities	45	40	42
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	3.29	-29	-14
Total Preferred & Common Equity	3.29	-29	-14
Preferred Stock	0.00	0.00	0.00
Total Common Equity	3.29	-29	-14
Common Stock	1,393	1,379	1,369
Retained Earnings	-1,390	-1,408	-1,382
Accumulated Other Comprehensive Income / (Loss)	0.01	0.01	-0.15

This table presents Rigel Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	139	128	127	115	117	124	116
Total Current Assets	106	95	92	95	101	107	110
Cash & Equivalents	52	36	26	45	49	40	30
Short-Term Investments	9.42	13	24	17	16	18	52
Accounts Receivable	31	29	28	24	21	29	16
Inventories, net	4.78	8.06	6.58	6.11	11	11	7.12
Prepaid Expenses	9.99	8.66	8.85	3.02	4.97	7.87	6.16
Plant, Property, & Equipment, net	0.10	0.12	0.14	0.19	0.22	0.29	1.69
Total Noncurrent Assets	33	34	34	20	16	16	3.48
Goodwill	28	28	29	14	14	15	-
Other Noncurrent Operating Assets	5.17	5.30	5.03	5.96	1.54	1.67	3.48
Total Liabilities & Shareholders' Equity	139	128	127	115	117	124	116
Total Liabilities	154	158	158	147	145	148	135
Total Current Liabilities	54	59	73	48	44	46	47
Short-Term Debt	0.00	0.00	15	-	-	-	-
Accounts Payable	3.82	6.13	9.28	8.00	5.24	6.30	2.72
Accrued Expenses	14	11	9.56	11	11	12	25
Current Deferred Revenue	1.36	1.36	1.36	1.36	1.36	1.37	1.37
Current Employee Benefit Liabilities	7.92	6.37	5.25	8.09	6.74	5.66	8.77
Other Current Liabilities	28	34	33	20	20	20	9.23
Total Noncurrent Liabilities	100	100	85	99	101	102	88
Long-Term Debt	60	60	45	60	60	59	39
Capital Lease Obligations	0.00	0.00	0.10	0.47	0.63	0.80	0.00
Other Noncurrent Operating Liabilities	40	40	40	39	41	42	49
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-15	-30	-32	-32	-28	-24	-20
Total Preferred & Common Equity	-15	-30	-32	-32	-28	-24	-20
Total Common Equity	-15	-30	-32	-32	-28	-24	-20
Common Stock	1,390	1,387	1,384	1,376	1,375	1,372	1,364
Retained Earnings	-1,404	-1,417	-1,416	-1,408	-1,403	-1,396	-1,384
Accumulated Other Comprehensive Income / (Loss)	0.01	-0.01	-0.01	-0.02	-0.03	-0.03	-0.29

This table displays calculated financial ratios and metrics derived from Rigel Pharmaceuticals' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	53.38%	-2.79%	-19.43%
EBITDA Growth	230.30%	63.87%	-394.39%
EBIT Growth	218.06%	63.11%	-344.54%
NOPAT Growth	260.57%	63.11%	-344.54%
Net Income Growth	169.69%	57.16%	-226.97%
EPS Growth	168.75%	57.16%	-226.97%
Operating Cash Flow Growth	647.99%	92.21%	-1,354.81%
Free Cash Flow Firm Growth	158.31%	75.36%	-212.53%
Invested Capital Growth	44.13%	18.19%	57.52%
Revenue Q/Q Growth	13.85%	-11.70%	34.54%
EBITDA Q/Q Growth	139.68%	-0.95%	29.71%
EBIT Q/Q Growth	154.57%	-0.55%	29.73%
NOPAT Q/Q Growth	142.36%	-0.55%	29.73%
Net Income Q/Q Growth	350.53%	-2.72%	29.10%
EPS Q/Q Growth	350.00%	-2.72%	29.10%
Operating Cash Flow Q/Q Growth	193.35%	73.18%	-3.98%
Free Cash Flow Firm Q/Q Growth	236.47%	52.49%	-21.65%
Invested Capital Q/Q Growth	10.23%	24.57%	49.36%
Profitability Metrics	-	-	-
Gross Margin	89.60%	93.92%	98.55%
EBITDA Margin	14.34%	-16.88%	-45.42%
Operating Margin	13.49%	-17.53%	-46.20%
EBIT Margin	13.49%	-17.53%	-46.20%
Profit (Net Income) Margin	9.75%	-21.47%	-48.71%
Tax Burden Percent	95.20%	100.00%	100.00%
Interest Burden Percent	75.92%	122.45%	105.44%
Effective Tax Rate	4.80%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-137.92%	118.75%	-699.05%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	17.21%	-16.29%	-36.84%
Return on Assets (ROA)	12.44%	-19.95%	-38.84%
Return on Common Equity (ROCE)	-137.92%	118.75%	-699.05%
Return on Equity Simple (ROE_SIMPLE)	531.78%	87.60%	430.18%
Net Operating Profit after Tax (NOPAT)	23	-14	-39
NOPAT Margin	12.85%	-12.27%	-32.34%
Net Nonoperating Expense Percent (NNEP)	-75.53%	-144.92%	-32.25%
Return On Investment Capital (ROIC_SIMPLE)	36.58%	-45.91%	-145.07%
Cost of Revenue to Revenue	10.40%	6.08%	1.45%
SG&A Expenses to Revenue	63.06%	90.47%	93.52%
R&D to Revenue	13.04%	20.98%	50.13%
Operating Expenses to Revenue	76.10%	111.45%	144.74%
Earnings before Interest and Taxes (EBIT)	24	-20	-56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	26	-20	-55
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	90.11	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.65	2.16	2.16
Price to Earnings (P/E)	16.95	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	5.90%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.55	2.19	2.01
Enterprise Value to EBITDA (EV/EBITDA)	10.84	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	11.52	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	12.10	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	8.85	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	23.83	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	18.15	-2.09	-2.97
Long-Term Debt to Equity	15.94	-1.84	-2.97
Financial Leverage	0.58	0.35	-7.28
Leverage Ratio	-11.09	-5.95	18.00
Compound Leverage Factor	-8.42	-7.29	18.98
Debt to Total Capital	94.78%	191.68%	150.80%
Short-Term Debt to Total Capital	11.55%	23.14%	0.00%
Long-Term Debt to Total Capital	83.23%	168.54%	150.80%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	5.22%	-91.68%	-50.80%
Debt to EBITDA	2.32	-3.04	-0.74
Net Debt to EBITDA	-0.69	-0.15	0.33
Long-Term Debt to EBITDA	2.04	-2.67	-0.74
Debt to NOPAT	2.59	-4.18	-1.04
Net Debt to NOPAT	-0.77	-0.21	0.46
Long-Term Debt to NOPAT	2.28	-3.67	-1.04
Altman Z-Score	-8.66	-14.88	-13.38
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	2.13	1.86	1.78
Quick Ratio	1.88	1.64	1.51
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	12	-20	-81
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	1.48	-2.92	-21.96
Operating Cash Flow to Interest Expense	3.97	-0.84	-19.90
Operating Cash Flow Less CapEx to Interest Expense	3.98	-0.80	-19.66
Efficiency Ratios	-	-	-
Asset Turnover	1.28	0.93	0.80
Accounts Receivable Turnover	4.97	3.30	4.31
Inventory Turnover	3.24	0.97	0.22
Fixed Asset Turnover	1,395.16	228.73	79.08
Accounts Payable Turnover	3.56	0.48	0.13
Days Sales Outstanding (DSO)	73.46	110.66	84.68
Days Inventory Outstanding (DIO)	112.79	375.78	1,641.77
Days Payable Outstanding (DPO)	102.58	761.06	2,744.60
Cash Conversion Cycle (CCC)	83.67	-274.62	-1,018.15
Capital & Investment Metrics	-	-	-
Invested Capital	-14	-26	-31
Invested Capital Turnover	-8.95	-4.09	-2.28
Increase / (Decrease) in Invested Capital	11	5.71	43
Enterprise Value (EV)	279	256	241
Market Capitalization	296	253	259
Book Value per Share	$0.19	($0.16)	($0.08)
Tangible Book Value per Share	($1.35)	($0.24)	($0.17)
Total Capital	63	31	27
Total Debt	60	60	40
Total Long-Term Debt	52	53	40
Net Debt	-18	2.95	-18
Capital Expenditures (CapEx)	-0.06	-0.26	-0.89
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.76	-3.71	-7.51
Debt-free Net Working Capital (DFNWC)	79	53	51
Net Working Capital (NWC)	72	46	51
Net Nonoperating Expense (NNE)	5.55	11	20
Net Nonoperating Obligations (NNO)	-18	2.95	-18
Total Depreciation and Amortization (D&A)	1.52	0.76	0.94
Debt-free, Cash-free Net Working Capital to Revenue	0.98%	-3.17%	-6.25%
Debt-free Net Working Capital to Revenue	44.11%	45.54%	42.16%
Net Working Capital to Revenue	40.05%	39.36%	42.16%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.99	($1.40)	($3.40)
Adjusted Weighted Average Basic Shares Outstanding	17.58M	17.40M	17.24M
Adjusted Diluted Earnings per Share	$0.99	($1.40)	($3.40)
Adjusted Weighted Average Diluted Shares Outstanding	17.69M	17.40M	17.24M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	17.86M	17.54M	17.37M
Normalized Net Operating Profit after Tax (NOPAT)	23	-14	-38
Normalized NOPAT Margin	12.85%	-12.27%	-31.57%
Pre Tax Income Margin	10.24%	-21.47%	-48.71%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	3.06	-2.98	-14.99
NOPAT to Interest Expense	2.91	-2.09	-10.49
EBIT Less CapEx to Interest Expense	3.06	-2.94	-14.74
NOPAT Less CapEx to Interest Expense	2.92	-2.05	-10.25
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Rigel Pharmaceuticals' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	60.92%	96.58%	37.03%	13.29%	-30.20%	25.54%	-9.84%	55.78%	151.25%	4.02%
EBITDA Growth	749.57%	441.23%	117.96%	45.55%	-8.47%	76.43%	60.34%	52.16%	110.45%	6.65%
EBIT Growth	747.15%	414.80%	108.49%	45.26%	-5.44%	75.74%	59.38%	51.54%	109.71%	6.99%
NOPAT Growth	747.15%	549.72%	108.49%	45.26%	-5.44%	75.74%	59.38%	51.54%	113.87%	6.99%
Net Income Growth	1,845.86%	318.22%	84.39%	39.07%	-47.39%	70.10%	51.08%	50.68%	106.19%	9.14%
EPS Growth	1,950.00%	312.12%	84.21%	37.50%	-47.39%	70.10%	51.08%	50.00%	106.19%	8.33%
Operating Cash Flow Growth	332.42%	1,695.22%	-94.91%	-23.05%	71.52%	89.78%	145.93%	84.11%	-14.79%	-29.17%
Free Cash Flow Firm Growth	241.96%	87.08%	63.30%	89.36%	90.74%	-27.02%	-199.75%	-151.35%	-161.19%	-142.38%
Invested Capital Growth	44.13%	53.06%	40.12%	5.31%	18.19%	45.07%	48.78%	68.07%	57.52%	15.74%
Revenue Q/Q Growth	4.14%	50.12%	24.74%	-17.48%	27.22%	4.64%	3.13%	-49.16%	128.82%	-24.85%
EBITDA Q/Q Growth	16.34%	1,520.20%	113.31%	-438.72%	146.73%	14.73%	59.66%	-669.41%	112.03%	-43.52%
EBIT Q/Q Growth	18.49%	3,044.52%	106.42%	-454.32%	144.03%	15.23%	58.61%	-712.07%	111.30%	-41.94%
NOPAT Q/Q Growth	18.49%	4,392.17%	106.42%	-348.03%	162.90%	15.23%	58.61%	-528.45%	116.14%	-41.94%
Net Income Q/Q Growth	15.46%	1,305.92%	87.51%	-1,219.00%	112.95%	13.76%	51.24%	-1,066.17%	107.36%	-41.10%
EPS Q/Q Growth	17.14%	1,266.67%	-20.00%	0.00%	112.95%	13.76%	51.24%	-900.00%	107.36%	-37.50%
Operating Cash Flow Q/Q Growth	-33.10%	7,078.48%	106.02%	19.66%	-359.16%	-122.92%	245.56%	81.40%	-64.72%	-3.02%
Free Cash Flow Firm Q/Q Growth	232.42%	68.21%	-107.84%	-62.26%	87.94%	9.74%	39.76%	-41.32%	-65.31%	-113.01%
Invested Capital Q/Q Growth	10.23%	17.26%	9.83%	16.58%	24.57%	-5.55%	-42.58%	27.93%	49.36%	1.59%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.95%	85.49%	92.38%	93.14%	89.41%	95.49%	96.00%	96.25%	99.33%	98.88%
EBITDA Margin	29.49%	26.39%	2.45%	-22.93%	5.59%	-15.21%	-18.66%	-47.70%	4.26%	-81.01%
Operating Margin	28.92%	25.41%	1.21%	-23.59%	5.49%	-15.87%	-19.59%	-48.81%	4.05%	-82.12%
EBIT Margin	28.92%	25.41%	1.21%	-23.59%	5.49%	-15.87%	-19.59%	-48.81%	4.05%	-82.12%
Profit (Net Income) Margin	24.90%	22.46%	-2.80%	-27.92%	2.06%	-20.23%	-24.55%	-51.92%	2.73%	-84.95%
Tax Burden Percent	94.21%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	91.40%	88.37%	-230.43%	118.39%	37.49%	127.48%	125.31%	106.37%	67.39%	103.45%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-137.92%	-16.70%	49.05%	70.81%	118.75%	94.55%	237.62%	511.64%	-699.05%	-553.79%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	36.87%	31.42%	1.29%	-22.70%	5.11%	-18.19%	-20.25%	-46.39%	3.23%	-48.58%
Return on Assets (ROA)	31.75%	27.77%	-2.97%	-26.87%	1.91%	-23.19%	-25.37%	-49.35%	2.18%	-50.26%
Return on Common Equity (ROCE)	-137.92%	-16.70%	49.05%	70.81%	118.75%	94.55%	237.62%	511.64%	-699.05%	-553.79%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-26.52%	47.58%	62.52%	0.00%	76.73%	134.35%	184.13%	0.00%	416.53%
Net Operating Profit after Tax (NOPAT)	17	14	0.31	-4.88	1.97	-3.13	-3.69	-8.91	2.08	-13
NOPAT Margin	28.92%	25.41%	0.85%	-16.51%	5.49%	-11.11%	-13.71%	-34.17%	4.05%	-57.48%
Net Nonoperating Expense Percent (NNEP)	-31.51%	-91.39%	41.74%	56.82%	-16.57%	-11.56%	-9.18%	-12.17%	-1.11%	-7.44%
Return On Investment Capital (ROIC_SIMPLE)	26.45%	-	-	-	6.29%	-	-	-	7.76%	-
Cost of Revenue to Revenue	10.05%	14.51%	7.62%	6.86%	10.59%	4.51%	4.00%	3.75%	0.67%	1.12%
SG&A Expenses to Revenue	51.25%	48.90%	76.13%	96.33%	75.02%	88.35%	97.84%	106.36%	62.74%	115.56%
R&D to Revenue	9.78%	11.18%	15.04%	20.40%	8.90%	23.01%	17.75%	38.70%	29.96%	65.44%
Operating Expenses to Revenue	61.03%	60.07%	91.17%	116.73%	83.92%	111.36%	115.59%	145.06%	95.28%	181.00%
Earnings before Interest and Taxes (EBIT)	17	14	0.45	-6.97	1.97	-4.47	-5.27	-13	2.08	-18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	17	15	0.90	-6.77	2.00	-4.28	-5.02	-12	2.18	-18
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	90.11	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.65	1.81	1.11	2.16	2.16	1.42	1.77	1.77	2.16	2.28
Price to Earnings (P/E)	16.95	73.35	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.90%	1.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	1.55	1.80	1.19	2.24	2.19	1.41	1.74	1.78	2.01	1.81
Enterprise Value to EBITDA (EV/EBITDA)	10.84	26.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	11.52	29.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	12.10	29.82	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	8.85	26.41	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	23.83	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	18.15	-4.08	-2.00	-1.89	-2.09	-1.89	-2.14	-2.49	-2.97	-1.99
Long-Term Debt to Equity	15.94	-4.08	-2.00	-1.42	-1.84	-1.89	-2.14	-2.49	-2.97	-1.99
Financial Leverage	0.58	0.08	-0.11	-0.21	0.35	0.86	2.00	4.36	-7.28	-5.54
Leverage Ratio	-11.09	-5.48	-4.23	-4.47	-5.95	-4.47	-7.71	-15.62	18.00	10.13
Compound Leverage Factor	-10.14	-4.84	9.75	-5.29	-2.23	-5.70	-9.66	-16.61	12.13	10.48
Debt to Total Capital	94.78%	132.43%	200.46%	212.63%	191.68%	212.52%	187.62%	167.33%	150.80%	201.02%
Short-Term Debt to Total Capital	11.55%	0.00%	0.00%	52.56%	23.14%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	83.23%	132.43%	200.46%	160.07%	168.54%	212.52%	187.62%	167.33%	150.80%	201.02%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	5.22%	-32.43%	-100.46%	-112.63%	-91.68%	-112.52%	-87.62%	-67.33%	-50.80%	-101.02%
Debt to EBITDA	2.32	5.57	-7.33	-4.25	-3.04	-3.08	-1.80	-1.47	-0.74	-0.51
Net Debt to EBITDA	-0.69	-0.13	-1.30	-0.73	-0.15	0.11	0.12	-0.04	0.33	0.54
Long-Term Debt to EBITDA	2.04	5.57	-7.33	-3.20	-2.67	-3.08	-1.80	-1.47	-0.74	-0.51
Debt to NOPAT	2.59	6.29	-9.46	-5.80	-4.18	-4.22	-2.51	-2.05	-1.04	-0.71
Net Debt to NOPAT	-0.77	-0.14	-1.68	-0.99	-0.21	0.16	0.17	-0.06	0.46	0.76
Long-Term Debt to NOPAT	2.28	6.29	-9.46	-4.36	-3.67	-4.22	-2.51	-2.05	-1.04	-0.71
Altman Z-Score	-8.81	-11.08	-13.54	-13.73	-14.25	-14.82	-14.33	-13.58	-11.96	-14.95
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.13	1.96	1.62	1.26	1.86	1.97	2.29	2.35	1.78	2.34
Quick Ratio	1.88	1.69	1.33	1.05	1.64	1.78	1.93	1.93	1.51	2.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	5.32	-4.02	-13	-6.08	-3.75	-31	-34	-57	-40	-24
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	2.72	-1.95	-6.23	-3.24	-1.96	-16.36	-18.49	-47.47	-36.53	-29.62
Operating Cash Flow to Interest Expense	7.42	10.52	0.15	-2.68	-3.27	-0.72	3.18	-3.38	-19.79	-16.10
Operating Cash Flow Less CapEx to Interest Expense	7.44	10.54	0.15	-2.68	-3.21	-0.70	3.18	-3.28	-19.48	-15.99
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.28	1.24	1.06	0.96	0.93	1.15	1.03	0.95	0.80	0.59
Accounts Receivable Turnover	4.97	5.82	5.24	4.23	3.30	6.78	6.66	5.81	4.31	5.86
Inventory Turnover	3.24	3.06	1.05	0.92	0.97	0.55	0.31	0.29	0.22	0.27
Fixed Asset Turnover	1,395.16	1,089.79	789.70	554.59	228.73	140.52	123.74	106.47	79.08	41.10
Accounts Payable Turnover	3.56	2.82	1.74	1.05	0.48	0.68	0.72	0.48	0.13	0.65
Days Sales Outstanding (DSO)	73.46	62.72	69.64	86.25	110.66	53.87	54.78	62.82	84.68	62.31
Days Inventory Outstanding (DIO)	112.79	119.45	347.67	394.98	375.78	659.23	1,173.41	1,249.90	1,641.77	1,363.55
Days Payable Outstanding (DPO)	102.58	129.51	209.81	348.33	761.06	534.24	510.43	764.26	2,744.60	565.13
Cash Conversion Cycle (CCC)	83.67	52.66	207.50	132.90	-274.62	178.86	717.76	548.46	-1,018.15	860.73
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-14	-16	-19	-21	-26	-34	-32	-23	-31	-62
Invested Capital Turnover	-8.95	-6.29	-5.05	-5.46	-4.09	-2.76	-2.66	-2.77	-2.28	-1.32
Increase / (Decrease) in Invested Capital	11	18	13	1.20	5.71	28	31	48	43	12
Enterprise Value (EV)	279	283	155	270	256	186	220	231	241	162
Market Capitalization	296	285	144	260	253	188	224	229	259	204
Book Value per Share	$0.19	($0.83)	($0.17)	($0.18)	($0.16)	($0.18)	($0.16)	($0.14)	($0.08)	($0.11)
Tangible Book Value per Share	($1.35)	($2.41)	($0.33)	($0.35)	($0.24)	($0.26)	($0.24)	($0.22)	($0.17)	($0.11)
Total Capital	63	45	30	28	31	28	32	36	27	20
Total Debt	60	60	60	60	60	60	60	60	40	39
Total Long-Term Debt	52	60	60	45	53	60	60	60	40	39
Net Debt	-18	-1.35	11	10	2.95	-2.23	-4.16	1.62	-18	-42
Capital Expenditures (CapEx)	-0.05	-0.03	0.00	0.00	-0.11	-0.02	0.00	-0.13	-0.35	-0.09
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.76	-8.96	-13	-15	-3.71	-16	-7.46	2.79	-7.51	-18
Debt-free Net Working Capital (DFNWC)	79	52	36	34	53	47	57	61	51	63
Net Working Capital (NWC)	72	52	36	19	46	47	57	61	51	63
Net Nonoperating Expense (NNE)	2.31	1.64	1.34	3.37	1.23	2.57	2.91	4.63	0.68	6.15
Net Nonoperating Obligations (NNO)	-18	-1.35	11	10	2.95	-2.23	-4.16	1.62	-18	-42
Total Depreciation and Amortization (D&A)	0.33	0.54	0.45	0.20	0.03	0.19	0.25	0.29	0.11	0.25
Debt-free, Cash-free Net Working Capital to Revenue	0.98%	-5.69%	-10.00%	-12.86%	-3.17%	-11.79%	-5.89%	2.15%	-6.25%	-20.66%
Debt-free Net Working Capital to Revenue	44.11%	33.12%	27.69%	28.31%	45.54%	35.32%	44.93%	47.43%	42.16%	70.69%
Net Working Capital to Revenue	40.05%	33.12%	27.69%	16.03%	39.36%	35.32%	44.93%	47.43%	42.16%	70.69%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.82	$0.71	($0.06)	($0.50)	$0.40	($0.30)	($0.40)	($0.80)	$0.80	($1.10)
Adjusted Weighted Average Basic Shares Outstanding	17.58M	17.60M	17.55M	17.52M	1.74M	17.44M	17.37M	17.36M	1.70M	17.28M
Adjusted Diluted Earnings per Share	$0.82	$0.70	($0.06)	($0.50)	$0.40	($0.30)	($0.40)	($0.80)	$0.80	($1.10)
Adjusted Weighted Average Diluted Shares Outstanding	17.69M	17.65M	17.55M	17.52M	1.74M	17.44M	17.37M	17.36M	1.70M	17.28M
Adjusted Basic & Diluted Earnings per Share	$0.82	$0.00	$0.00	$0.00	$0.40	$0.00	$0.00	$0.00	$0.80	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	17.86M	17.62M	17.59M	17.54M	17.54M	17.44M	17.44M	17.37M	17.37M	17.28M
Normalized Net Operating Profit after Tax (NOPAT)	12	9.84	0.31	-4.88	1.38	-3.13	-3.69	-8.91	1.46	-13
Normalized NOPAT Margin	20.24%	17.79%	0.85%	-16.51%	3.85%	-11.11%	-13.71%	-34.17%	2.84%	-57.48%
Pre Tax Income Margin	26.43%	22.46%	-2.80%	-27.92%	2.06%	-20.23%	-24.55%	-51.92%	2.73%	-84.95%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	8.52	6.82	0.22	-3.72	1.03	-2.35	-2.83	-10.57	1.88	-22.28
NOPAT to Interest Expense	8.52	6.82	0.15	-2.60	1.03	-1.65	-1.98	-7.40	1.88	-15.60
EBIT Less CapEx to Interest Expense	8.54	6.84	0.22	-3.72	1.09	-2.34	-2.83	-10.46	2.19	-22.17
NOPAT Less CapEx to Interest Expense	8.54	6.84	0.15	-2.60	1.09	-1.63	-1.98	-7.29	2.19	-15.49
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Rigel Pharmaceuticals' Financials

When does Rigel Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Rigel Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Rigel Pharmaceuticals' net income changed over the last 2 years?

Rigel Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of $17.49 million in 2024, falling from -$58.57 million in 2022. The previous period was -$25.09 million in 2023. Find out what analysts predict for Rigel Pharmaceuticals in the coming months.

What is Rigel Pharmaceuticals's operating income?

Rigel Pharmaceuticals's total operating income in 2024 was $24.19 million, based on the following breakdown:

Total Gross Profit: $160.63 million
Total Operating Expenses: $136.44 million

How has Rigel Pharmaceuticals revenue changed over the last 2 years?

Over the last 2 years, Rigel Pharmaceuticals' total revenue changed from $120.24 million in 2022 to $179.28 million in 2024, a change of 49.1%.

How much debt does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals' total liabilities were at $160.69 million at the end of 2024, a 10.2% increase from 2023, and a 8.7% increase since 2022.

How much cash does Rigel Pharmaceuticals have?

In the past 2 years, Rigel Pharmaceuticals' cash and equivalents has ranged from $24.46 million in 2022 to $56.75 million in 2024, and is currently $56.75 million as of their latest financial filing in 2024.

How has Rigel Pharmaceuticals' book value per share changed over the last 2 years?

Over the last 2 years, Rigel Pharmaceuticals' book value per share changed from -0.08 in 2022 to 0.19 in 2024, a change of -336.9%.

Related Companies

This page (NASDAQ:RIGL) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rigel Pharmaceuticals (RIGL) Financials

Frequently Asked Questions About Rigel Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rigel Pharmaceuticals (RIGL) Financials

Annual Income Statements for Rigel Pharmaceuticals

Quarterly Income Statements for Rigel Pharmaceuticals

Annual Cash Flow Statements for Rigel Pharmaceuticals

Quarterly Cash Flow Statements for Rigel Pharmaceuticals

Annual Balance Sheets for Rigel Pharmaceuticals

Quarterly Balance Sheets for Rigel Pharmaceuticals

Annual Metrics And Ratios for Rigel Pharmaceuticals

Quarterly Metrics And Ratios for Rigel Pharmaceuticals

Frequently Asked Questions About Rigel Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools